博創科技(300548.SZ):終止與Sicoya公司等設合資公司
格隆匯11月24日丨博創科技(300548.SZ)公佈,此前公吿披露,公司於2020年2月24日召開的第四屆董事會第二十次會議審議通過了《關於投資設立合資公司的議案》,公司與Sicoya GmbH (“Sicoya 公司”)、陝西源傑半導體技術有限公司等達成意向協議,由各方共同出資成立合資公司。
自上述各方簽署《合資意向協議》後,公司積極與協議各方就相關事項進行了溝通和協商。但因合作方Sicoya 公司股東層面發生變化,原合資意向協議無法繼續執行。公司綜合考慮各方面因素,決定終止本次對外投資事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.